World's Best Scientists 2026 revealed!

D-Index & Metrics

Neuroscience

D-Index
61
Citations
14343
World Ranking
3662
National Ranking
327

Richard Appleton publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where Richard Appleton sits on this spectrum.

38–47 publications: 18 scientists 48–57 publications: 79 scientists 58–67 publications: 193 scientists 68–77 publications: 323 scientists 78–87 publications: 406 scientists 88–97 publications: 452 scientists 98–107 publications: 539 scientists 108–117 publications: 505 scientists 118–127 publications: 522 scientists 128–137 publications: 469 scientists 138–147 publications: 456 scientists 148–157 publications: 459 scientists 158–167 publications: 397 scientists 168–177 publications: 383 scientists 178–187 publications: 350 scientists 188–197 publications: 302 scientists 198–207 publications: 306 scientists 208–217 publications: 262 scientists 218–227 publications: 242 scientists 228–237 publications: 220 scientists 238–247 publications: 203 scientists 248–257 publications: 174 scientists 258–267 publications: 176 scientists 268–277 publications: 175 scientists 278–287 publications: 125 scientists 288–297 publications: 116 scientists 298–307 publications: 127 scientists 308–317 publications: 128 scientists 318–327 publications: 99 scientists 328–337 publications: 89 scientists 338–347 publications: 78 scientists 348–357 publications: 96 scientists 358–367 publications: 66 scientists 368–377 publications: 59 scientists 378–387 publications: 65 scientists 388–397 publications: 54 scientists 398–407 publications: 48 scientists 408–417 publications: 49 scientists 418–427 publications: 34 scientists 428–437 publications: 31 scientists 438–447 publications: 30 scientists 448–457 publications: 31 scientists 458–467 publications: 36 scientists 468–477 publications: 40 scientists 478–487 publications: 35 scientists 488–497 publications: 30 scientists 498–507 publications: 23 scientists 508–517 publications: 26 scientists 518–527 publications: 20 scientists 528–537 publications: 23 scientists 538–547 publications: 20 scientists 548–557 publications: 20 scientists 558–567 publications: 17 scientists 568–577 publications: 14 scientists 578–587 publications: 20 scientists 588–597 publications: 20 scientists 598–607 publications: 19 scientists 608–617 publications: 18 scientists 618–627 publications: 17 scientists 628–637 publications: 11 scientists 638–647 publications: 11 scientists 648–657 publications: 11 scientists 658–667 publications: 8 scientists 668–677 publications: 7 scientists 678–687 publications: 11 scientists 688–697 publications: 10 scientists 698–707 publications: 4 scientists 708–717 publications: 6 scientists 718–727 publications: 5 scientists 728–737 publications: 5 scientists 738–747 publications: 9 scientists 748–757 publications: 9 scientists 758–767 publications: 3 scientists 768–777 publications: 7 scientists 778–787 publications: 7 scientists 788–797 publications: 6 scientists 798–807 publications: 2 scientists 808–817 publications: 2 scientists 818–827 publications: 7 scientists 828–837 publications: 0 scientists 838–847 publications: 9 scientists 848–857 publications: 3 scientists 858–867 publications: 1 scientists 868–877 publications: 3 scientists 878–886 publications: 6 scientists 887+ publications: 100 scientists
38 publications 887+

This scientist: 270 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 887 publications or more.

Richard Appleton D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where Richard Appleton sits on this spectrum.

30–31 D-Index: 42 scientists 32–33 D-Index: 172 scientists 34–35 D-Index: 296 scientists 36–37 D-Index: 435 scientists 38–39 D-Index: 459 scientists 40–41 D-Index: 456 scientists 42–43 D-Index: 467 scientists 44–45 D-Index: 478 scientists 46–47 D-Index: 512 scientists 48–49 D-Index: 435 scientists 50–51 D-Index: 425 scientists 52–53 D-Index: 418 scientists 54–55 D-Index: 392 scientists 56–57 D-Index: 357 scientists 58–59 D-Index: 334 scientists 60–61 D-Index: 328 scientists 62–63 D-Index: 260 scientists 64–65 D-Index: 278 scientists 66–67 D-Index: 239 scientists 68–69 D-Index: 250 scientists 70–71 D-Index: 210 scientists 72–73 D-Index: 200 scientists 74–75 D-Index: 189 scientists 76–77 D-Index: 170 scientists 78–79 D-Index: 146 scientists 80–81 D-Index: 113 scientists 82–83 D-Index: 126 scientists 84–85 D-Index: 100 scientists 86–87 D-Index: 84 scientists 88–89 D-Index: 99 scientists 90–91 D-Index: 84 scientists 92–93 D-Index: 85 scientists 94–95 D-Index: 72 scientists 96–97 D-Index: 76 scientists 98–99 D-Index: 45 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 43 scientists 104–105 D-Index: 32 scientists 106–107 D-Index: 45 scientists 108–109 D-Index: 50 scientists 110–111 D-Index: 32 scientists 112–113 D-Index: 39 scientists 114–115 D-Index: 32 scientists 116–117 D-Index: 29 scientists 118–119 D-Index: 27 scientists 120–121 D-Index: 19 scientists 122–123 D-Index: 23 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 16 scientists 128–129 D-Index: 24 scientists 130–131 D-Index: 13 scientists 132–133 D-Index: 21 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 14 scientists 138–139 D-Index: 15 scientists 140–141 D-Index: 10 scientists 142–143 D-Index: 10 scientists 144–145 D-Index: 13 scientists 146–147 D-Index: 9 scientists 148–149 D-Index: 8 scientists 150–151 D-Index: 6 scientists 152–153 D-Index: 6 scientists 154–155 D-Index: 7 scientists 156–157 D-Index: 7 scientists 158–159 D-Index: 10 scientists 160–161 D-Index: 4 scientists 162 D-Index: 8 scientists 163+ D-Index: 100 scientists
30 D-Index 163+

This scientist: 61 D-Index — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 163 D-Index or more.

Overview

Richard Appleton is affiliated with Alder Hey Children's Hospital in the United Kingdom and has contributed extensively to the field of medicine, with a focus on pediatrics, perinatology, and child health. Their research primarily centers on epilepsy research and treatment, pharmacological effects and toxicity studies, and related topics including hemoglobinopathies, neonatal and fetal brain pathology, ethics in clinical research, pharmaceutical studies and practices, and drug transport and resistance mechanisms.

Appleton's body of work includes significant contributions to epilepsy treatment and emergency medical protocols for children. Their recent publications cover clinical trials and reviews related to epilepsy drugs and emergency treatments:

  • The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial (2021) - The Lancet
  • The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial (2021) - The Lancet
  • Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs (2021) - Health Technology Assessment
  • Levetiracetam as an alternative to phenytoin for second-line emergency treatment of children with convulsive status epilepticus: the EcLiPSE RCT (2020) - Health Technology Assessment
  • Optimal Management of Status Epilepticus in Children in the Emergency Setting: A Review of Recent Advances (2022) - Open Access Emergency Medicine

Appleton has frequently published in well-known venues such as The Lancet, Health Technology Assessment, Emergency Medicine Journal, Open Access Emergency Medicine, and Archives of Disease in Childhood Education & Practice.

Collaboration appears as a significant component of their work, with frequent co-authors including Richard Brown, Stephen Howell, Melissa Maguire, Anthony G Marson, and Girvan Burnside.

Best Publications

  • The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial.

    Anthony G Marson;Asya M Al-Kharusi;Muna Alwaidh;Richard Appleton

  • The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial

    Anthony G Marson;Asya M Al-Kharusi;Muna Alwaidh;Richard Appleton

  • Safety and efficacy of buccal midazolam versus rectal diazepam for emergency treatment of seizures in children: a randomised controlled trial.

    John McIntyre;Sue Robertson;Elizabeth Norris;Richard Appleton

  • Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome.

    Orrin Devinsky;Anup D. Patel;Elizabeth A. Thiele;Matthew H. Wong

  • Febrile seizures: an update

    C Waruiru;R Appleton

  • THE TREATMENT OF SLEEP DISORDERS WITH MELATONIN

    J E Jan;H Espezel;R E Appleton

  • Randomised, Placebo‐Controlled Study of Vigabatrin as First‐Line Treatment of Infantile Spasms

    R. E. Appleton;A. C. B. Peters;J. P. Mumford;D. E. Shaw

  • Drug management for acute tonic-clonic convulsions including convulsive status epilepticus in children.

    Amy McTague;Timothy Martland;Richard Appleton

  • Melatonin for sleep problems in children with neurodevelopmental disorders: randomised double masked placebo controlled trial.

    P Gringras;C Gamble;A P Jones;L Wiggs

  • Nonconvulsive status epilepticus: Epilepsy Research Foundation Workshop Reports

    Matthew Walker;Helen Cross;Shelagh Smith;Camilla Young

  • Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology

    Claudia B. Catarino;Joan Y.W. Liu;Ioannis Liagkouras;Vaneesha S. Gibbons

  • Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial

    Mark D. Lyttle;Mark D. Lyttle;Naomi E A. Rainford;Carrol. Gamble;Shrouk. Messahel

  • Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease

    Shahd H. M. Hamid;Dan Whittam;Mariyam Saviour;Amal Alorainy

  • The relationship between treatment with valproate, lamotrigine, and topiramate and the prognosis of the idiopathic generalised epilepsies

    A Nicolson;R E Appleton;D W Chadwick;D F Smith

  • LORAZEPAM VERSUS DIAZEPAM IN THE ACUTE TREATMENT OF EPILEPTIC SEIZURES AND STATUS EPILEPTICUS

    R Appleton;A Sweeney;I Choonara;J Robson

  • The treatment of convulsive status epilepticus in children. The Status Epilepticus Working Party, Members of the Status Epilepticus Working Party.

    R Appleton;I Choonara;T Martland;B Phillips

  • Molecular mechanisms and phenotypic variation in RYR1-related congenital myopathies

    Haiyan Zhou;Heinz Jungbluth;Caroline A. Sewry;Lucy Feng

  • The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.

    Anthony Marson;Girvan Burnside;Richard Appleton;Dave Smith

  • A review of the current literature and a guide to the early diagnosis of autoimmune disorders associated with neuromyelitis optica

    Anand Iyer;Liene Elsone;Richard Appleton;Anu Jacob

  • The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.

    Anthony Marson;Girvan Burnside;Richard Appleton;Dave Smith

  • Gabapentin as Add‐On Therapy in Children with Refractory Partial Seizures: A 12‐Week, Multicentre, Double‐Blind, Placebo‐Controlled Study

    Richard Appleton;Klaus Fichtner;Linda LaMoreaux;Jeannine Alexander

  • Best practice guidelines for the management of women with epilepsy

    P Crawford;R Appleton;T Betts;J Duncan

  • Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients

    Liene Elsone;Jay Panicker;Kerry Mutch;Mike Boggild

  • Migrating partial seizures of infancy: expansion of the electroclinical, radiological and pathological disease spectrum.

    Amy McTague;Amy McTague;Richard Appleton;Shivaram Avula;J. Helen Cross;J. Helen Cross

Frequent Co-Authors

Anthony G Marson
Anthony G Marson University of Liverpool
Paula R Williamson
Paula R Williamson University of Liverpool
Gus A. Baker
Gus A. Baker University of Liverpool
Peter Camfield
Peter Camfield Dalhousie University
Graeme J. Sills
Graeme J. Sills University of Glasgow
David Chadwick
David Chadwick University of Liverpool
J. Helen Cross
J. Helen Cross Great Ormond Street Hospital
Munir Pirmohamed
Munir Pirmohamed University of Liverpool
Bridget Young
Bridget Young University of Liverpool
Ingrid E. Scheffer
Ingrid E. Scheffer University of Melbourne

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Richard Appleton

Trending Scientists

Recently Published Articles